Here are the 424B prospectus supplements from Boston Scientific Corporation (BSX) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow BSX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BSX filings page.
Penumbra, Inc. has agreed to be acquired by Boston Scientific Corporation in a cash-and-stock merger. Under the Agreement and Plan of Merger, each issued and outstanding Penumbra share (other than excluded shares) will be converted into the right to receive either $374.00 in cash or 3.8721 Boston Scientific shares, subject to a proration mechanism that allocates 73.26% of outstanding Penumbra shares to cash consideration and 26.74% to stock consideration.
The Special Meeting of Penumbra stockholders is scheduled for May 6, 2026 to vote on adoption of the merger agreement. Boston Scientific is expected to issue approximately 43,866,267 shares in the transaction, with former Penumbra stockholders holding about 2.87% of Boston Scientific post-close, based on figures as of March 27, 2026.